| Content | Title | Link | Categories |
|---|---|---|---|
| Society for Neuro-Oncology 2022 | The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients with Leptomeningeal Metastasis Having Solid Tumors; Implications for Treating the LM Tumor with Anti_HER2 Therapy | Breast Cancer, CNS Metastases | |
Society for Neuro-Oncology 2022 | The Detection of Disseminated Pineal Parenchymal Tumor of Intermediate Differentiation (PPTID) in Cerebrospinal Fluid (CSF) Using Cell Capture and Immunocytochemistry | CNS Metastases | |
Society for Neuro-Oncology 2022 | Detection of Mutant p53 Positive Glioblastoma Cells in Cerebrospinal Fluid (CSF) Using a Microfluidic Based Immunoassay | CNS Metastases | |
Clinical Breast Cancer 2022 | Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ Assay | CNS Metastases | |
American Academy of Neurology 2022 | Using Cerebrospinal Fluid Tumor Cell (CSF-TC) Assays to Track Disease Burden and Treatment Response in Patients with Leptomeningeal Metastasis | CNS Metastases | |
San Antonio Breast Cancer Symposium 2021 | Characterization of HER2 Amplification in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease in Stage IV Patients with Breast Cancer | Breast Cancer, CNS Metastases | |
Society for Neuro-Oncology 2021 | Case Series of Multi-Institutional Utility of CNSide™ to Manage Leptomeningeal Disease in Patients with Metastatic Breast Cancer | Breast Cancer, CNS Metastases | |
SNO Brain Metastases 2021 | Beyond Cytology – A Single Institution Experience Using CNSide™ for Diagnosing and Monitoring Treatment Response in Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis (LMC) | CNS Metastases | |
Molecular Med Tri-Con 2021 | Detection of EGFR Mutations in Quantity Insufficient Tissue Slides by High Sensitivity Assay Target Selector™ in Patients with Non-Small Cell Lung Cancer | Lung Cancer | |
ASCO 2020 | Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF) | Technology Platform | |
International Association for the Study of Lung Cancer (IASLC) 2020 | Utility of Liquid Biopsy in Diagnosis and Treatment Response in EGFR Mutant NSCLC Patients with Leptomeningeal Involvement | Lung Cancer | |
Society for Neuro-Oncology 2020 | Target Selector™ cerebrospinal fluid (CSF) circulating tumor cells and biomarker analysis: improving sensitivity and targeted treatment options in breast and NSCLC cancer patients with CNS involvement | Lung Cancer | |
San Antonio Breast Cancer Virtual Symposium 2020 | HER2 Expression in Matched Metastatic Tumor and Circulating Tumor Cells (CTCs) In Breast Cancer: Implications for profiling and monitoring of HER2 status | Breast Cancer | |
University of Missouri at Kansas City, Kansas City 2019 | Clinical utility of circulating tumor cell (CTC) analysis in patients with metastatic NSCLC receiving first-line chemotherapy | Lung Cancer | |
UC San Diego Health System 2019 | Surrogate or Not: The Role for Cell Free Circulating DNA in Detecting EGFR Mutations Present in Tumor Tissue | Biomarkers | |
PLOS ONE 2019 | Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations | Lung Cancer | |
Clinics in Oncology – Breast Cancer 2019 | Clinical Utility of Target Selector™ Circulating Tumor Cell (CTC) Testing in Tumor Marker Gene Amplification and Protein Expression in Metastatic Breast Cancer Management | Breast Cancer | |
Clinics in Oncology – General Oncology 2019 | Demonstrated Clinical Utility of Target Selector™ ctDNA Testing: Liquid Biopsy EGFR Mutation Detection Enabled Targeted Therapy Selection for Three Advanced NSCLC | Lung Cancer | |
AMP 2019 | Highly sensitive and specific detection of Cytokeratin Positive and Negative Circulating Tumor Cells | Technology Platform | |
AMP 2019 | Target Selector™ DNA EGFR kit for tissue demonstrates high sensitivity without the need for macro-dissection | Biomarkers | |
AMP 2019 | Mutant-p53 antibody stains cytokeratin negative CTCs enriched and detected with a “Pan-CTC” antibody cocktail | Biomarkers | |
AMP 2019 | Detection of Potential Epithelial Mesenchymal Transition Cells in Localized Prostate Cancer | Prostate Cancer | |
AMP 2019 | Monitoring breast cancer biomarkers from circulating tumor DNA using Target Selector™ NGS Breast Panel | Breast Cancer | |
AMP 2019 | Validation of Target Selector™ Next Generation Sequencing Lung Panelfor the Detection of Circulating Tumor TNA Alterations | Lung Cancer | |
AACR 2019 | Validation of a highly sensitive Target Selector™ ctDNA assay for ESR1 resistance mutations using an NGS enrichment strategy | Biomarkers | |
World Conference in Lung Cancer 2019 | The Dynamic Range of Mutant Allele Fraction Detected in Patients with NSCLC: Clinical Experience Data and Clinical Implications | Lung Cancer | |
San Antonio Breast Cancer Symposium 2019 | Clinical Data in Over 1,500 Patients Across All Stages of Breast Cancer with Target Selector™ Circulating Tumor Cell Technology | Breast Cancer | |
Oncology & Hematology Review 2018 | Detecting an ALK Rearrangement via Liquid Biopsy Enabled a Targeted Therapy-based Approach for Treating a Patient with Advanced Non-small Cell Lung Cancer | Lung Cancer | |
Journal of Thoracic Oncology 2018 | ROS-1 Rearrangements in Circulating Tumor Cells | Biomarkers | |
Biomarkers Summit 2018 | Microfluidic Assay Detects dMMR in Circulating Tumor Cells (CTCs) | Biomarkers | |
AACR-IASLC 2018 | Validation of the QuantStudio5 Instrument for Use in Biocept’s TargetSelector™ ctDNA Lung Cancer Assays | Technology Platform | |
AACR 2018 | TargetSelector™ CTC technology demonstrates clinical utility in monitoring treatment response in germ cell tumors (testicular cancer) | Technology Platform | |
AACR 2018 | Validation of Highly Sensitive Target Selector™ ctDNA Assays for EGFR, BRAF, and KRAS Mutations | Biomarkers | |
World Conference in Lung Cancer 2018 | Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM | Lung Cancer | |
Journal of Thoracic Oncology 2017 | Clinical Utility of Plasma EGFR T790M Mutation Detection in Advanced Non-Small Cell Lung Cancer Patients According to RECIST Criteria | Lung Cancer | |
ASCO 2017 | Biocept’s Sample Collection for Tumor Cell Analysis Demonstrates Superior Performance | Technology Platform | |
ASCO 2017 | Clinical Experience in ctDNA Profiling of NSCLC 2000 Cases Using TargetSelector™ Demonstrates High Sensitivity | Lung Cancer | |
AACR 2017 | A concordance study of the ArcherDx Reveal ctDNA 28 NGS panel and Biocept’s Target-Selector™ mutation assay using ctDNA collected in Biocept’s CEE-sure blood collection tube | Technology Platform | |
ESMO 2016 | Clinical evaluation of the utility of a liquid biopsy (Circulating tumoral cells and ctDNA) to determine the mutational profile (EGFR, KRAS, ALK, ROS1 and BRAF) in advanced NSCLC patients. | Lung Cancer | |
ASCO 2016 | The performance of a comprehensive CTC anti-body capture cocktail in the detection and phenotypic analysis of CTCs | Technology Platform | |
San Antonio Breast Cancer Symposium 2016 | Circulating Tumor Cell (CTC) Biomarker Evaluation from Patients with Metastatic Breast Cancer (MBC) Utilizing the Target Selector™ Platform | Breast Cancer | |
Clinical Translational Oncology 2015 | Correlation of hormone receptor status between circulating tumor cells, primary tumor and metastasis in breast cancer patients | Breast Cancer | |
ASCO 2015 | Clinical validation and utility of a liquid biopsy for non-small cell lung carcinoma utilizing CTCs and ctDNA to analyze ALK, ROS and EGFR status | Lung Cancer | |
AACR 2015 | High Sensitivity Detection of Rare EGFR Mutations with ctDNA using Target-Selector™ Assays | Biomarkers | |
Molecular Assay Development 2015 | Validation of PD-L1 Expression on Circulating Tumor Cells in Lung Cancer | Lung Cancer | |
San Antonio Breast Cancer Symposium 2014 | Prospective characterization of HER2-positive circulating tumor cells in patients with HER2- negative metastatic breast cancer | Breast Cancer | |
Cancer Cell 2014 | Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread | Ovarian Cancer | |
Cancer Medicine 2013 | Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer | Biomarkers | |
ASCO 2012 | Estrogen receptor and progesterone receptor immunocytochemistry staining in circulating tumor cells as compared to primary tumor or metastatic biopsy | Biomarkers | |
ASCO 2012 | Detection of discordant HER2 status by FISH in circulating tumor cells and disseminated tumor cells in early stage breast cancer using a microfluidicbased cell enrichment and extraction platform (OncoCEE™) | Biomarkers | |
ASCO 2012 | Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing | Breast Cancer | |
AACR 2012 | The CEE-Selector™ Assay: A tool for the identification of rare allele variants | Technology Platform | |
San Antonio Breast Cancer Symposium 2011 | Estrogen receptor and progesterone receptor immunocytochemistry staining in circulating tumor cells as compared to primary tumor or metastatic biopsy | Biomarkers | |
San Antonio Breast Cancer Symposium 2011 | Detection of HER2 gene amplification in circulating tumor cells and disseminated tumor cells by fluorescence in situ hybridization using OncoCEE™ | Biomarkers | |
Molecular Med Tri-Con 2011 | Detection of EpCAM-negative and Cytokeratin-negative Circulating Tumor Cells in Peripheral Blood | Technology Platform | |
Cancer Genetics 2011 | FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform | Biomarkers | |
Cancer Discovery 2011 | A Novel Platform for Detection of CK+ and CK- CTCs | Technology Platform | |
Biomicrofluidics 2011 | Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device | Technology Platform | |
Biomicrofluidics 2011 | Efficient Capture of Suspended Tumor Cells with a Novel Immunocytochemical Microfluidic Device | Technology Platform | |
ASCO 2011 | Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISH | Technology Platform | |
ASCO 2011 | Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology [CEE™]) | Biomarkers | |
AACR 2011 | Fluorescence labeling of cytokeratin-negative circulating tumor cells in peripheral blood: A new paradigm for the study of cancer progression | Technology Platform | |
AACR 2011 | Redefining CTCs: Detection of cytokeratin-negative circulating tumor cells (CTCs) | Technology Platform | |
The Journal of Urology 2010 | Recovery of Circulating Tumor Cells in Urothelial Carcinoma Cell Lines Utilizing a Novel Antibody Based Microfluidic Cell Capture Technique | Technology Platform | |
San Antonio Breast Cancer Symposium 2010 | Detection of circulating tumor cells and HER2 gene amplification status in breast cancer using a novel microfluidic platform (Cell Enrichment and Extraction Technology, CEE™) | Biomarkers | |
| CEE™ Cell Enrichment and Extraction Technology Enabling Early, Non-invasive Isolationof Rare Cells for Diagnostics | Technology Platform | ||
| Mouse Models for MEMS (Micro-Electro-Mechanical System) Based Biomarker Discovery: A Novel CTC Mouse-Trap | Technology Platform | ||
| Comparison of fluorescence in situ hybridization of estrogen receptor genetic locus with protein expression in invasive breast carcinoma | Technology Platform |